789 related articles for article (PubMed ID: 31050706)
1. Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents.
Di Pino A; DeFronzo RA
Endocr Rev; 2019 Dec; 40(6):1447-1467. PubMed ID: 31050706
[TBL] [Abstract][Full Text] [Related]
2. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
3. Metformin and pioglitazone: Effectively treating insulin resistance.
Staels B
Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
[TBL] [Abstract][Full Text] [Related]
4. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
5. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
Stolar MW; Chilton RJ
Clin Ther; 2003; 25 Suppl B():B4-31. PubMed ID: 14553864
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
[TBL] [Abstract][Full Text] [Related]
7. Effects of the thiazolidinedione medications on micro- and macrovascular complications in patients with diabetes--update 2008.
Rohatgi A; McGuire DK
Cardiovasc Drugs Ther; 2008 Jun; 22(3):233-40. PubMed ID: 18373186
[TBL] [Abstract][Full Text] [Related]
8. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
Defronzo RA; Mehta RJ; Schnure JJ
Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
[TBL] [Abstract][Full Text] [Related]
9. The PROactive trial (PROspective pioglitAzone Clinical Trial In macroVascular Events): what does it mean for primary care physicians?
Singaram V; Pratley R
Diab Vasc Dis Res; 2007 Sep; 4(3):237-40. PubMed ID: 17907116
[TBL] [Abstract][Full Text] [Related]
10. Does pioglitazone prevent macrovascular events in patients with type 2 diabetes?
Hiralal R; Koo KK; Gerstein HC
CMAJ; 2006 Apr; 174(8):1090-1. PubMed ID: 16606956
[No Abstract] [Full Text] [Related]
11. A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications.
Molavi B; Rassouli N; Bagwe S; Rasouli N
Vasc Health Risk Manag; 2007; 3(6):967-73. PubMed ID: 18200815
[TBL] [Abstract][Full Text] [Related]
12. Effects of the thiazolidinediones on cardiovascular risk factors.
Gilling L; Suwattee P; DeSouza C; Asnani S; Fonseca V
Am J Cardiovasc Drugs; 2002; 2(3):149-56. PubMed ID: 14727977
[TBL] [Abstract][Full Text] [Related]
13. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
Mudaliar S; Henry RR
Annu Rev Med; 2001; 52():239-57. PubMed ID: 11160777
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
Derosa G; Maffioli P
Curr Mol Pharmacol; 2012 Jun; 5(2):272-81. PubMed ID: 22122457
[TBL] [Abstract][Full Text] [Related]
15. Early combination therapy with a thiazolidinedione for the treatment of type 2 diabetes.
Kanzer-Lewis G
Diabetes Educ; 2003; 29(6):954-8, 961. PubMed ID: 14692369
[No Abstract] [Full Text] [Related]
16. Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.
Henry RR
Clin Ther; 2003; 25 Suppl B():B47-63. PubMed ID: 14553866
[TBL] [Abstract][Full Text] [Related]
17. Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?
Doggrell SA
Expert Opin Pharmacother; 2008 Feb; 9(3):405-20. PubMed ID: 18220491
[TBL] [Abstract][Full Text] [Related]
18. Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.
Viberti G
J Diabetes Complications; 2005; 19(3):168-77. PubMed ID: 15866064
[TBL] [Abstract][Full Text] [Related]
19. High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone.
Pfützner A; Schöndorf T; Hanefeld M; Forst T
J Diabetes Sci Technol; 2010 May; 4(3):706-16. PubMed ID: 20513338
[TBL] [Abstract][Full Text] [Related]
20. Pioglitazone: a review of its use in type 2 diabetes mellitus.
Waugh J; Keating GM; Plosker GL; Easthope S; Robinson DM
Drugs; 2006; 66(1):85-109. PubMed ID: 16398569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
